X

Drug Profile

Research programme: therapeutic antibodies - Medarex/Organon

Latest Information Update: 25 Jan 2010

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medarex; Organon
Developer Medarex; Schering-Plough
Class
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Autoimmune disorders; Cancer

Most Recent Events

02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
19 Nov 2007 Organon has been acquired and merged into Schering-Plough
21 May 2007 Organon and Medarex have amended their agreement to develop therapeutic antibodies for the treatment of cancer and autoimmune disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com